Compare Davita Inc (DVA) vs 8x8 Inc (EGHT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs 8x8 Inc — how do they compare? Davita Inc trades at $175.04 (market cap $11.28B), while 8x8 Inc trades at $2.2 (market cap $307.65M). The key difference: Davita Inc is far larger — about 36.7× 8x8 Inc's market cap, and 8x8 Inc is more actively traded (750,629 versus 650,294). Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and 8x8 Inc for 16 Days on average.
| DVA | EGHT | |
|---|---|---|
Market Cap | $11.28B | $307.65M |
Volume | 650,294 | 750,629 |
Sector | Health | Technology |
52-Week High | $240.96 | $2.76 |
52-Week Low | $103.87 | $1.59 |
Typical Hold Time | 113 Days | 16 Days |
Enterprise Value | $24.00B | $574.57M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $177.02, down 1.87% on the day, showing mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company demonstrates strong earnings beats with Q2 2026 EPS of $4.02 exceeding expectations of $3.88, while revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026. Recent developments include expanding value-based care partnerships with Humana, potentially benefiting over 10,000 Medicare Advantage members.
The outlook remains cautiously optimistic with 43% analyst buy ratings and a $235.67 consensus price target suggesting 33% upside. However, rising debt-to-asset ratios (65.55% in 2025) and margin pressures from Q2 2026 create headwinds. Key risks include regulatory changes in healthcare reimbursement and competitive pressures in dialysis services.
EGHT trades at $2.14, down 1.38% today, with a bullish technical signal from moving averages and strong momentum indicators. The company shows improving fundamentals with three consecutive quarterly EPS beats and projected profitability in 2026. Recent news highlights cost-saving client implementations and AI product growth, while analyst consensus targets $19.77 with mixed ratings.
The outlook suggests potential upside if profitability materializes as projected, supported by operational efficiency gains and AI adoption. Key risks include high debt levels, negative cash flow, and competitive pressures in the communications software sector that could challenge margin expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About 8x8 Inc
8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.
Read more on EGHT →
